Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$883.20 USD
-7.48 (-0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $881.43 -1.77 (-0.20%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10,845 | 7,742 | 5,695 | 3,587 | 3,214 |
Receivables | 5,667 | 5,329 | 6,037 | 4,115 | 2,672 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2,581 | 2,402 | 1,951 | 1,917 | 1,416 |
Other Current Assets | 387 | 411 | 332 | 161 | 387 |
Total Current Assets | 19,479 | 15,884 | 14,015 | 9,779 | 7,689 |
Net Property & Equipment | 4,146 | 3,763 | 3,482 | 3,222 | 2,890 |
Investments & Advances | 5,397 | 6,592 | 6,838 | 3,136 | 3,257 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2,575 | 1,724 | 877 | 859 | 824 |
Intangibles | 1,039 | 916 | 0 | 0 | 0 |
Deposits & Other Assets | 444 | 336 | 223 | 168 | 145 |
Total Assets | 33,080 | 29,215 | 25,435 | 17,163 | 14,805 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 607 | 589 | 564 | 476 | 418 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 720 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2,817 | 2,552 | 2,649 | 2,222 | 1,679 |
Total Current Liabilities | 3,423 | 3,141 | 3,933 | 2,697 | 2,097 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 127 | 70 | 73 | 58 | 619 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,983 | 1,981 | 1,980 | 1,979 | 0 |
Non-Current Capital Leases | 720 | 720 | 0 | 717 | 714 |
Other Non-Current Liabilities | 854 | 638 | 680 | 687 | 286 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7,107 | 6,551 | 6,666 | 6,138 | 3,716 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 11,354 | 9,949 | 8,088 | 6,716 | 4,429 |
Retained Earnings | 27,260 | 23,307 | 18,968 | 10,893 | 7,380 |
Other Equity | -81 | -239 | -26 | 29 | 21 |
Treasury Stock | 12,560 | 10,353 | 8,261 | 6,613 | 740 |
Total Shareholder's Equity | 25,973 | 22,664 | 18,769 | 11,025 | 11,090 |
Total Liabilities & Shareholder's Equity | 33,080 | 29,215 | 25,435 | 17,163 | 14,805 |
Total Common Equity | 25,973 | 22,664 | 18,769 | 11,025 | 11,090 |
Shares Outstanding | 109.70 | 109.30 | 108.50 | 107.10 | 110.20 |
Book Value Per Share | 236.76 | 207.36 | 172.98 | 102.94 | 100.63 |
Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 10,845 | 9,914 | 8,928 | 8,960 |
Receivables | NA | 5,667 | 5,585 | 5,121 | 5,119 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 2,581 | 2,562 | 2,508 | 2,425 |
Other Current Assets | NA | 387 | 575 | 366 | 406 |
Total Current Assets | NA | 19,479 | 18,635 | 16,923 | 16,909 |
Net Property & Equipment | NA | 4,146 | 4,006 | 3,923 | 3,881 |
Investments & Advances | NA | 5,397 | 5,779 | 6,327 | 6,067 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 2,575 | 2,317 | 2,139 | 1,925 |
Intangibles | NA | 1,039 | 1,017 | 953 | 929 |
Deposits & Other Assets | NA | 444 | 410 | 393 | 350 |
Total Assets | NA | 33,080 | 32,163 | 30,658 | 30,060 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 607 | 537 | 547 | 600 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2,817 | 3,062 | 2,557 | 2,501 |
Total Current Liabilities | NA | 3,423 | 3,599 | 3,104 | 3,100 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 127 | 125 | 116 | 86 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1,983 | 1,983 | 1,982 | 1,982 |
Non-Current Capital Leases | NA | 720 | 720 | 720 | 720 |
Other Non-Current Liabilities | NA | 832 | 717 | 677 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 7,107 | 7,259 | 6,640 | 6,565 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 11,354 | 11,252 | 10,889 | 10,598 |
Retained Earnings | NA | 27,260 | 26,101 | 25,093 | 24,125 |
Other Equity | NA | -81 | -177 | -198 | -182 |
Treasury Stock | NA | 12,560 | 12,271 | 11,766 | 11,046 |
Total Shareholder's Equity | NA | 25,973 | 24,904 | 24,018 | 23,495 |
Total Liabilities & Shareholder's Equity | NA | 33,080 | 32,163 | 30,658 | 30,060 |
Total Common Equity | 0 | 25,973 | 24,904 | 24,018 | 23,495 |
Shares Outstanding | 109.70 | 109.70 | 108.90 | 108.50 | 109.70 |
Book Value Per Share | 0.00 | 236.76 | 228.69 | 221.36 | 214.18 |